CAS NO: | 1137868-52-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | TAK-960 is an orally available, selective inhibitor ofpolo-like kinase1 (PLK1), with anIC50of 0.8 nM. TAK-960 also shows inhibitory activities againstPLK2andPLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiplecancercell lines and exhibits significant efficacy against multiple tumor xenografts[1]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | TAK-960 treatment causes accumulation of G2-M cells, aberrant polo mitosis morphology, and increased phosphorylation of histone H3 (pHH3). TAK-960 (2-1000 nM; 72 hours) inhibits proliferation of multiple cancer cell lines, with mean EC50values ranging from 8.4 to 46.9 nM, but not in nondividing normal cells[1]. Cell Viability Assay[1]
| ||||||||||||||||
体内研究 (In Vivo) | TAK-960 exhibits (10 mg/kg; p.o.; once daily for 2 weeks) significant efficacy against multiple tumor xenografts[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 561.60 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C27H34F3N7O3 | ||||||||||||||||
CAS 号 | 1137868-52-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 16.67 mg/mL(29.68 mM;ultrasonic and warming and heat to 60℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |